A groundbreaking treatment for vitiligo just cleared a major regulatory hurdle in Europe, offering patients the first systemic medication specifically designed to treat this chronic autoimmune skin disease. On June 29, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending approval of upadacitinib (RINVOQ) 15 mg, once daily, for adults and adolescents with non-segmental vitiligo (NSV). If the European Commission grants final approval in the coming months, this will mark a significant shift in how doctors treat a condition that has long lacked effective systemic options.

What Is Non-Segmental Vitiligo and Why Does It Matter?

Vitiligo is an autoimmune disease in which the body's immune system mistakenly attacks melanocytes, the cells responsible for producing skin pigment. This results in white patches of skin that can appear anywhere on the body and progress unpredictably over time. Non-segmental vitiligo, which accounts for approximately 84% of all vitiligo cases, is characterized by symmetrical white patches that often appear on the face, hands, feet, and other visible areas. Unlike segmental vitiligo, which tends to stabilize, non-segmental vitiligo can continue spreading even after years of stability, creating significant uncertainty for patients.

Beyond the physical symptoms, vitiligo carries a heavy psychological burden. Many patients report that the condition profoundly affects their confidence, identity, and daily life. Despite its immune-mediated nature, vitiligo is often dismissed as merely a cosmetic problem, which can lead to stigma and social isolation. Currently, there are no approved systemic medicines specifically designed to treat vitiligo's underlying immune dysfunction, leaving patients with limited options.

How Did Upadacitinib Perform in Clinical Trials?

The CHMP's positive opinion is based on data from the Phase 3 Viti-Up clinical program, which included two replicate randomized, placebo-controlled studies. A total of 614 participants with non-segmental vitiligo across 90 sites worldwide were enrolled in these trials. In the first 48 weeks of treatment, upadacitinib 15 mg met both co-primary endpoints, demonstrating significant repigmentation improvements.

The specific endpoints measured were:

• Total Body Repigmentation (T-VASI 50): Participants achieved at least a 50% improvement in total body vitiligo area, indicating substantial overall skin repigmentation.
• Facial Repigmentation (F-VASI 75): Participants achieved at least a 75% improvement in facial vitiligo area, showing particularly strong results in this cosmetically sensitive region.
• Safety Profile: The safety profile of upadacitinib 15 mg was consistent with that observed in the drug's approved uses for other conditions, with no new safety signals reported.

These results represent a meaningful advance because facial vitiligo often has the greatest impact on patients' quality of life and self-image. The 75% improvement threshold for facial repigmentation reflects the clinical importance of treating visible areas.

What Is Upadacitinib and How Does It Work?

Upadacitinib is a JAK inhibitor, a class of medication that works by blocking specific enzymes involved in immune system signaling. JAK stands for Janus kinase, and these enzymes play a central role in how immune cells communicate and coordinate their attacks on the body's own tissues. By inhibiting JAK-1 more potently than other JAK enzymes, upadacitinib helps calm the overactive immune response that drives vitiligo. The drug is already approved in the European Union for several other autoimmune and inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, and inflammatory bowel diseases.

"Vitiligo is an autoimmune skin disease with high stigma and significant burden to patients with limited treatment options available. A positive opinion for upadacitinib in non-segmental vitiligo is an important step forward in providing patients with a systemic treatment option," said Roopal Thakkar, executive vice president of research and development and chief scientific officer at AbbVie.

Roopal Thakkar, Executive Vice President, Research and Development, Chief Scientific Officer, AbbVie

What Are the Next Steps Toward Patient Access?

While the CHMP positive opinion is encouraging, it is not yet a final approval. The European Commission must still make a formal decision, which is expected in the coming months. This final step typically follows the CHMP recommendation but is not guaranteed, though positive CHMP opinions are generally followed by Commission approval. Once approved, upadacitinib would become the first systemic treatment specifically indicated for non-segmental vitiligo in the European Union, potentially transforming treatment options for the millions of patients living with this condition.

It is worth noting that upadacitinib is also under regulatory review for other autoimmune skin conditions. In June 2026, AbbVie also announced a positive CHMP opinion for upadacitinib in severe alopecia areata, another autoimmune hair loss condition, with Phase 3 data showing that both 15 mg and 30 mg doses met primary endpoints for hair regrowth at week 24.

How to Prepare for Potential Treatment Options

If you or a loved one has non-segmental vitiligo, here are steps to consider as new treatment options become available:

• Consult Your Dermatologist: Schedule an appointment with a dermatologist to discuss your current treatment plan and ask about emerging systemic therapies. Your doctor can assess whether you are a candidate for JAK inhibitors based on your overall health and medical history.
• Understand Your Vitiligo Type: Confirm with your doctor whether you have non-segmental or segmental vitiligo, as treatment recommendations may differ. Non-segmental vitiligo, the more common form, is the focus of this new approval.
• Track Your Symptoms: Keep a record of where vitiligo patches appear, how quickly they spread, and how the condition affects your daily life and emotional well-being. This information will help your doctor determine the best treatment approach and monitor response to therapy.
• Stay Informed About Regulatory Decisions: Monitor announcements from the European Commission regarding final approval of upadacitinib for vitiligo. Once approved, your doctor can discuss whether this treatment is appropriate for your specific situation.

The approval of a first-in-class systemic treatment for vitiligo represents a watershed moment for patients who have long relied on topical creams, light therapy, and other limited options. By addressing the underlying immune dysfunction rather than just the symptoms, upadacitinib offers a fundamentally different approach to managing this unpredictable autoimmune disease.